

# VÃ-ctor Vinuesa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5875245/publications.pdf>

Version: 2024-02-01

130  
papers

2,625  
citations

257429

24  
h-index

276858

41  
g-index

131  
all docs

131  
docs citations

131  
times ranked

4063  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). <i>Lancet Infectious Diseases</i> , The, 2019, 19, e260-e272.	9.1	285
2	Field evaluation of a rapid antigen test (Panbio, COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. <i>Clinical Microbiology and Infection</i> , 2021, 27, 472.e7-472.e10.	6.0	245
3	Evaluation of a rapid antigen test (Panbio, COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic close contacts of COVID-19 patients. <i>Clinical Microbiology and Infection</i> , 2021, 27, 636.e1-636.e4.	6.0	120
4	Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation. <i>Haematologica</i> , 2019, 104, 2155-2163.	3.5	82
5	Pooling of nasopharyngeal swab specimens for SARS-CoV-2 detection by RT-PCR. <i>Journal of Medical Virology</i> , 2020, 92, 2306-2307.	5.0	72
6	High-resolution mapping of tuberculosis transmission: Whole genome sequencing and phylogenetic modelling of a cohort from Valencia Region, Spain. <i>PLoS Medicine</i> , 2019, 16, e1002961.	8.4	62
7	SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients. <i>Journal of Clinical Virology</i> , 2020, 131, 104611.	3.1	61
8	Early Post-Transplant Torquetenovirus Viremia Predicts Cytomegalovirus Reactivations In Solid Organ Transplant Recipients. <i>Scientific Reports</i> , 2018, 8, 15490.	3.3	59
9	Monitoring of alphatorquevirus DNA levels for the prediction of immunosuppression-related complications after kidney transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 1139-1149.	4.7	57
10	Early detection of SARS-CoV-2 infection cases or outbreaks at nursing homes by targeted wastewater tracking. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1061-1063.	6.0	49
11	Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. <i>American Journal of Transplantation</i> , 2019, 19, 2479-2494.	4.7	45
12	Dynamics of Torque Teno virus plasma DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Clinical Virology</i> , 2017, 94, 22-28.	3.1	44
13	Whole-genome sequencing of <i>Mycobacterium tuberculosis</i> directly from clinical samples for high-resolution genomic epidemiology and drug resistance surveillance: an observational study. <i>Lancet Microbe</i> , The, 2020, 1, e175-e183.	7.3	42
14	Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1894-1903.	5.8	36
15	Point-of-care evaluation of a rapid antigen test (CLINITEST COVID-19 Rapid COVID-19 Antigen Test) for diagnosis of SARS-CoV-2 infection in symptomatic and asymptomatic individuals. <i>Journal of Infection</i> , 2021, 82, e11-e12.	3.3	35
16	Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1620-1623.	3.0	34
17	Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. <i>Blood Reviews</i> , 2016, 30, 35-48.	5.7	34
18	Recent Advances in Iron Chelation and Gallium-Based Therapies for Antibiotic Resistant Bacterial Infections. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2876.	4.1	32

#	ARTICLE	IF	CITATIONS
19	Expanding role of cytomegalovirus as a human pathogen. <i>Journal of Medical Virology</i> , 2016, 88, 1103-1112.	5.0	31
20	Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 563-570.	2.0	31
21	Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant. <i>Journal of Infection</i> , 2022, 84, e64-e66.	3.3	30
22	Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice. <i>Transplant International</i> , 2015, 28, 1042-1054.	1.6	29
23	Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting. <i>Journal of General Virology</i> , 2015, 96, 2822-2831.	2.9	29
24	The molecular epidemiology of HIV-1 in the Comunidad Valenciana (Spain): analysis of transmission clusters. <i>Scientific Reports</i> , 2017, 7, 11584.	3.3	29
25	Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESCICH survey. <i>Transplant Infectious Disease</i> , 2017, 19, e12773.	1.7	26
26	B- and T-cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing-home residents. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1672-1677.	6.0	26
27	Monitoring of Trough Plasma Ganciclovir Levels and Peripheral Blood Cytomegalovirus (CMV)-Specific CD8 <sup>+</sup> T Cells To Predict CMV DNAemia Clearance in Preemptively Treated Allogeneic Stem Cell Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5602-5605.	3.2	24
28	Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. <i>Transplant Infectious Disease</i> , 2018, 20, e12926.	1.7	24
29	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. <i>Bone Marrow Transplantation</i> , 2020, 55, 2147-2159.	2.4	24
30	Evaluation of a rapid antigen detection test (Panbio, COVID-19 Ag Rapid Test Device) as a point-of-care diagnostic tool for COVID-19 in a pediatric emergency department. <i>Journal of Medical Virology</i> , 2021, 93, 6803-6807.	5.0	24
31	Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 2885-2894.	4.7	22
32	Going beyond serology for stratifying the risk of CMV infection in transplant recipients. <i>Reviews in Medical Virology</i> , 2019, 29, e2017.	8.3	22
33	Comparison of the performance of 2 commercial multiplex PCR platforms for detection of respiratory viruses in upper and lower tract respiratory specimens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 40-43.	1.8	21
34	Upper respiratory tract SARS-CoV-2 RNA loads in symptomatic and asymptomatic children and adults. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1858.e1-1858.e7.	6.0	20
35	Kinetics of Alphatorquevirus plasma DNAemia at late times after allogeneic hematopoietic stem cell transplantation. <i>Medical Microbiology and Immunology</i> , 2019, 208, 253-258.	4.8	19
36	Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2017, 19, e12717.	1.7	18

#	ARTICLE	IF	CITATIONS
37	Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?. <i>Annals of Hematology</i> , 2017, 96, 1253-1270.	1.8	18
38	Longitudinal analysis of human cytomegalovirus glycoprotein B (gB)-specific and neutralizing antibodies in AIDS patients either with or without cytomegalovirus end-organ disease. <i>Journal of Medical Virology</i> , 2001, 64, 35-41.	5.0	17
39	Expansion of the CRF19_cpx Variant in Spain. <i>Journal of Clinical Virology</i> , 2015, 69, 146-149.	3.1	17
40	A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study. <i>Transplant Infectious Disease</i> , 2017, 19, e12729.	1.7	17
41	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13158.	1.7	17
42	Comparative evaluation of molecular methods for the quantitative measure of torquetenovirus viremia, the new surrogate marker of immune competence. <i>Journal of Medical Virology</i> , 2022, 94, 491-498.	5.0	17
43	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , 2019, 78, 393-401.	3.3	17
44	SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant Recipients Recovered from COVID-19.. <i>Transplantation</i> , 2021, Publish Ahead of Print, 1372-1380.	1.0	17
45	T cell-mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19. <i>American Journal of Transplantation</i> , 2021, 21, 2785-2794.	4.7	17
46	Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty® COVID-19 vaccine in nursing home residents. <i>Clinical Microbiology and Infection</i> , 2022, 28, 279-284.	6.0	17
47	Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant. <i>Journal of Medical Virology</i> , 2001, 65, 77-84.	5.0	16
48	Early kinetics of Torque Teno virus DNA load and BK polyomavirus viremia after kidney transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13240.	1.7	16
49	Qualitative assessment of SARS-CoV-2-specific antibody avidity by lateral flow immunochromatographic IgG/IgM antibody assay. <i>Journal of Medical Virology</i> , 2021, 93, 1141-1144.	5.0	16
50	Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain. <i>Journal of Clinical Microbiology</i> , 2015, 53, 2741-2744.	3.9	15
51	Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , 2018, 90, 1438-1443.	5.0	15
52	Short-term incubation of positive blood cultures in brain-heart infusion broth accelerates identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass-spectrometry. <i>Journal of Medical Microbiology</i> , 2017, 66, 1752-1758.	1.8	15
53	Dynamics of SARS-CoV-2-Spike-reactive antibody and T-cell responses in chronic kidney disease patients within 3 months after COVID-19 full vaccination. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1562-1573.	2.9	15
54	Hydrogen- and Methane-Based Breath Testing and Outcomes in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 319-327.	1.7	14

#	ARTICLE	IF	CITATIONS
55	Antibody response to human cytomegalovirus (HCMV) glycoprotein B (gB) in AIDS patients with HCMV end-organ disease. , 1998, 55, 272-280.		13
56	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. Bone Marrow Transplantation, 2020, 55, 431-440.	2.4	13
57	Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with postâ€transplantation cyclophosphamide. Transplant Infectious Disease, 2020, 22, e13206.	1.7	13
58	Identification of a large, fast-expanding HIV-1 subtype B transmission cluster among MSM in Valencia, Spain. PLoS ONE, 2017, 12, e0171062.	2.5	13
59	Intra- and Interinstitutional Evaluation of an Etest for Vancomycin Minimum Inhibitory Concentration Measurement inStaphylococcus aureusBlood Isolates: Figure 1.. Clinical Infectious Diseases, 2015, 61, 1490-1492.	5.8	12
60	Comparison of the artus Epsteinâ€Barr virus (EBV) PCR kit and the Abbott RealTime EBV assay for measuring plasma EBV DNA loads in allogeneic stem cell transplant recipients. Diagnostic Microbiology and Infectious Disease, 2017, 88, 36-38.	1.8	12
61	Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigational Approach. Clinical Infectious Diseases, 2018, 67, 805-807.	5.8	12
62	Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. Bone Marrow Transplantation, 2019, 54, 90-98.	2.4	12
63	Suitability of two rapid lateral flow immunochromatographic assays for predicting SARSâ€CoVâ€2 neutralizing activity of sera. Journal of Medical Virology, 2021, 93, 2301-2306.	5.0	12
64	Monitoring of Torque Teno virus DNAemia in critically ill COVID-19 patients: May it help to predict clinical outcomes?. Journal of Clinical Virology, 2022, 148, 105082.	3.1	12
65	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1022-1030.	2.0	11
66	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. Biology of Blood and Marrow Transplantation, 2020, 26, 972-977.	2.0	11
67	Amplification of human Î²â€glucuronidase gene for appraising the accuracy of negative SARSâ€CoVâ€2 RTâ€PCR results in upper respiratory tract specimens. Journal of Medical Virology, 2021, 93, 48-50.	5.0	11
68	Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. American Journal of Transplantation, 2021, 21, 258-271.	4.7	11
69	Bacterial metabolites trimethylamine N-oxide and butyrate as surrogates of small intestinal bacterial overgrowth in patients with a recent decompensated heart failure. Scientific Reports, 2021, 11, 6110.	3.3	11
70	IL28B genetic variation and cytomegalovirusâ€specific Tâ€cell immunity in allogeneic stem cell transplant recipients. Journal of Medical Virology, 2017, 89, 685-695.	5.0	10
71	Caveats in interpreting SARSâ€CoVâ€2 IgM<sup>+</sup>/IgG<sup>â€</sup> antibody profile in asymptomatic health care workers. Journal of Medical Virology, 2021, 93, 634-636.	5.0	10
72	The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. Journal of General Virology, 2017, 98, 2530-2542.	2.9	10

#	ARTICLE	IF	CITATIONS
73	Performance of an automated human immunodeficiency virus (HIV) antigen/antibody combined assay for prenatal screening for HIV infection in pregnant women. <i>Journal of Medical Microbiology</i> , 2009, 58, 1529-1530.	1.8	9
74	Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?. <i>Journal of Clinical Virology</i> , 2017, 97, 26-32.	3.1	9
75	Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention Study. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	9
76	Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1347-1356.	2.4	9
77	COVID-19 infodemics: the role of mainstream and social media. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1568-1569.	6.0	9
78	Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients. <i>Journal of Clinical Virology</i> , 2021, 142, 104943.	3.1	9
79	RNA viral loads of SARS-CoV-2 Alpha and Delta variants in nasopharyngeal specimens at diagnosis stratified by age, clinical presentation and vaccination status. <i>Journal of Infection</i> , 2022, 84, 579-613.	3.3	9
80	An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2020, 209, 15-21.	4.8	8
81	Diversity and dynamic changes of anelloviruses in plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , 2021, 93, 5167-5172.	5.0	8
82	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 538-550.	1.3	8
83	Applying lessons learned from cytomegalovirus infection in transplant patients to vaccine design. <i>Drug Discovery Today</i> , 2016, 21, 674-681.	6.4	7
84	Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) proteomic profiling of cerebrospinal fluid in the diagnosis of enteroviral meningitis: a proof-of-principle study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2331-2339.	2.9	7
85	Missing Cases of Herpes Simplex Virus (HSV) Infection of the Central Nervous System When the Reller Criteria Are Applied for HSV PCR Testing: a Multicenter Study. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	7
86	Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 23, e13507.	1.7	7
87	Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13301.	1.7	7
88	The clinical benefit of instituting a prospective clinical community-acquired respiratory virus surveillance program in allogeneic hematopoietic stem cell transplantation. <i>Journal of Infection</i> , 2020, 80, 333-341.	3.3	7
89	Performance of a MALDI-TOF mass spectrometry-based method for rapid detection of third-generation oxymino-cephalosporin-resistant <i>Escherichia coli</i> and <i>Klebsiella</i> spp. from blood cultures. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1925-1932.	2.9	7
90	Human genetic polymorphisms and risk of viral infection after solid organ transplantation.. <i>Transplantation Reviews</i> , 2022, 36, 100669.	2.9	7

#	ARTICLE	IF	CITATIONS
91	Early adjustment of empirical antibiotic therapy of bloodstream infections on the basis of direct identification of bacteria by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and Gram staining results. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 963-969.	1.7	6
92	Initial viral load and decay kinetics of SARS-CoV-2 lineage B.1.1.7 in the upper respiratory tract of adults and children. <i>Journal of Infection</i> , 2021, 83, 496-522.	3.3	6
93	Plasma metabolomics profiling for the prediction of cytomegalovirus DNAemia and analysis of virus-host interaction in allogeneic stem cell transplant recipients. <i>Journal of General Virology</i> , 2015, 96, 3373-3381.	2.9	6
94	Enumeration of NKG2C+natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia. <i>Journal of Medical Virology</i> , 2015, 87, 1601-1607.	5.0	5
95	Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?. <i>Bone Marrow Transplantation</i> , 2018, 53, 787-790.	2.4	5
96	Are pathogenic intestinal bacteria present in stool specimens from patients with chronic heart failure?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 141-143.	1.8	5
97	A survey on practices for active surveillance of carriage of multidrug-resistant bacteria in hospitals in the Autonomous Community of Valencia, Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2069-2074.	2.9	5
98	Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against <i>Candida</i> spp. and <i>Aspergillus</i> spp. in Allogeneic Stem Cell Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 740-747.	2.0	5
99	Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 22-27.	1.8	5
100	Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. <i>Transplant Infectious Disease</i> , 2021, 23, e13627.	1.7	5
101	Impact of time elapsed since full vaccination on SARS-CoV-2 RNA load in Delta-variant breakthrough COVID-19. <i>Journal of Infection</i> , 2022, 84, 579-613.	3.3	5
102	Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. <i>Blood Advances</i> , 2022, 6, 848-853.	5.2	5
103	Lack of evidence for a reciprocal interaction between bacterial and cytomegalovirus infection in the allogeneic stem cell transplantation setting. <i>Transplant International</i> , 2016, 29, 1196-1204.	1.6	4
104	Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?. <i>Transplant Infectious Disease</i> , 2020, 22, e13440.	1.7	4
105	Fundamentos e implementaci3n de Programas de Optimizaci3n de Diagn3stico Microbiol3gico. <i>Enfermedades Infecciosas Y MicrobiologAa Cl3nica</i> , 2021, 39, 248-251.	0.5	4
106	Diagnostic significance of SARS-CoV-2 IgM positive/IgG negative antibody profile in symptomatic patients with suspected COVID-19 testing negative by RT-PCR. <i>Journal of Infection</i> , 2021, 82, e15-e16.	3.3	4
107	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <i>EJHaem</i> , 2021, 2, 236-248.	1.0	4
108	Inhibition of LpxC Increases the Activity of Iron Chelators and Gallium Nitrate in Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Antibiotics</i> , 2021, 10, 609.	3.7	4

#	ARTICLE	IF	CITATIONS
109	Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib. <i>British Journal of Haematology</i> , 2021, 195, 637-641.	2.5	4
110	Field performance of the Abbott RealTime MTB assay for the diagnosis of extrapulmonary tuberculosis in a low-prevalence setting. <i>Enfermedades Infecciosas Y MicrobiologĂa ClĂnica</i> , 2020, 38, 206-211.	0.5	4
111	Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2018, 90, 1375-1382.	5.0	3
112	Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2019, 208, 405-414.	4.8	3
113	Spontaneously resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes. <i>Journal of Medical Virology</i> , 2019, 91, 1128-1135.	5.0	3
114	Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. <i>Bone Marrow Transplantation</i> , 2021, 56, 1281-1290.	2.4	3
115	Real-life evaluation of a rapid extraction-free SARS-CoV-2 RT-PCR assay (COVID-19 PCR Fast) for the diagnosis of COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 5233-5235.	5.0	3
116	Evolution of SARS-CoV-2 immune responses in nursing home residents following full dose of the Comirnaty <sup>®</sup> COVID-19 vaccine. <i>Journal of Infection</i> , 2022, 84, 418-467.	3.3	3
117	Human pegivirus type 1 infection in kidney transplant recipients: Replication kinetics and clinical correlates. <i>Transplant Infectious Disease</i> , 2022, 24, .	1.7	3
118	Active Cytomegalovirus Infection in Nonimmunosuppressed Patients in the ICU. <i>Chest</i> , 2011, 140, 269-270.	0.8	2
119	Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2019, 219, 1510-1512.	4.0	2
120	Clinical significance of <i>Pneumocystis jirovecii</i> DNA detection by real-time PCR in hematological patient respiratory specimens. <i>Journal of Infection</i> , 2020, 80, 578-606.	3.3	2
121	A New Clinical and Immunovirological Score for Predicting the Risk of Late Severe Infection in Solid Organ Transplant Recipients: The CLIV Score. <i>Journal of Infectious Diseases</i> , 2020, 222, 479-487.	4.0	2
122	Assessing the potential association between SARS-CoV-2 RNA load in the respiratory tract and COVID-19 mortality. <i>Journal of Medical Virology</i> , 2021, 93, 1862-1864.	5.0	2
123	Assessing the risk of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients by monitoring oxidative-stress markers in plasma. <i>Journal of General Virology</i> , 2017, 98, 1855-1863.	2.9	2
124	Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Medical Microbiology</i> , 2018, 67, 814-819.	1.8	2
125	Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1493-1496.	2.4	2
126	SARS-CoV-2 adaptive immunity in nursing home residents up to eight months after two doses of the Comirnaty <sup>®</sup> COVID-19 vaccine. <i>Journal of Infection</i> , 2022, 84, 834-872.	3.3	2



#	ARTICLE	IF	CITATIONS
127	Pathogen Safety of Long-Term Treatments for Bleeding Disorders: (Un)Predictable Risks and Evolving Threats. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 973-973.	2.7	1
128	The Culpability of Respiratory Viruses in Pneumonia-Related Acute Respiratory Failure. <i>Chest</i> , 2018, 154, 223.	0.8	0
129	Cytomegalovirus DNAemia in patients with <i>de novo</i> acute myeloid leukemia undergoing cytotoxic chemotherapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 3081-3083.	1.3	0
130	Adoption of new technologies in laboratory workflow practices for positive blood culture bottles: a cross-sectional survey among hospitals in the Autonomous Community of Valencia, Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1199-1202.	2.9	0